# A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Source: https://onco.cc/trials/nct04762069/  
OnCo record `nct04762069` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Berubicin in glioma & glioblastoma, run by CNS Pharmaceuticals, Inc., active and no longer recruiting.

## Summary

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme is a phase 2 interventional study registered as NCT04762069 by CNS Pharmaceuticals, Inc., with 252 participants enrolled, started 2021-05-18 and due to reach its primary completion in 2026-04-27. Interventions recorded: Berubicin and Lomustine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04762069
- Phase: 2
- Setting: A Multicenter, Open-Label Study With a Randomized Control Arm of the Efficacy, Safety, and Pharmacokinetics of Intravenously Infused Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme After Failure of Standard First Line Therapy
- Sponsor: CNS Pharmaceuticals, Inc.
- Enrolled: 252

## Sources

- ClinicalTrials.gov NCT04762069: https://clinicaltrials.gov/study/NCT04762069

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct04762069.json